RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC
RELAY+ revealed a favorable benefit-risk profile for RAM plus GEF in East Asian patients with untreated <i>EGFR</i>-mutated metastatic NSCLC, supporting RAM plus GEF as an alternative first-line treatment option, particularly in those with an L858R mutation.
Authors
- Kazuto Nishio (ORCID: https://orcid.org/0000-0002-8275-0846)
- Kazuo Kasahara (ORCID: https://orcid.org/0000-0001-5551-1543)
- S. Varughese (ORCID: https://orcid.org/0000-0002-0851-5709)
- K. Nishino
- Sotaro Enatsu
- Miyako Satouchi (ORCID: https://orcid.org/0000-0003-0613-9487)
- E.B. Garon
- Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0003-3742-5419)
- Kiyotaka Yoh (ORCID: https://orcid.org/0000-0001-6928-357X)
- M. Reck
- Kazuhiko Nakagawa
- Kazuko Sakai
- Carla Visseren‐Grul (ORCID: https://orcid.org/0000-0003-2010-1514)
- Makoto Nishio (ORCID: https://orcid.org/0000-0003-4969-4165)
- Michelle Carlsen
- Tomoko Matsui (ORCID: https://orcid.org/0000-0002-2448-9280)
- Takashi Seto
Institutions
- Eli Lilly (United States) (US)
- National Hospital Organization Kyushu Cancer Center (JP)
- Eli Lilly (Japan) (JP)
- Eli Lilly (India) (IN)
- Eli Lilly (Netherlands) (NL)
- German Center for Lung Research (DE)
- The Cancer Institute Hospital (JP)
- National Cancer Center Hospital East (JP)
- Osaka International Cancer Institute (JP)
- Nippon Medical School Hospital (JP)
- Hyogo Prefectural Cancer Center (JP)
- Japanese Foundation For Cancer Research (JP)
- Kindai University (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100912
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00